Global Information
회사소개 | 문의 | 위시리스트

세계의 전립선암 치료 시장

Prostate Cancer Therapeutics

리서치사 Global Industry Analysts, Inc.
발행일 2019년 05월 상품 코드 360715
페이지 정보 영문 339 Pages
가격
US $ 5,600 ₩ 6,728,000 PDF by E-mail (Single User License) help
DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로 1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste 가 되지 않으며, 인쇄는 1회에 한해 가능합니다. 인쇄물 이용은 PDF 라이선스 소유자로 한정됩니다.
US $ 16,800 ₩ 20,185,000 PDF by E-mail (Global License to Company and its Fully-owned Subsidiaries) help
동일 기업 및 100% 자회사의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수 제한은 없습니다. PDF 파일은 Copy & Paste 가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.

주의 : 본 보고서는 DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로, 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



세계의 전립선암 치료 시장 Prostate Cancer Therapeutics
발행일 : 2019년 05월 페이지 정보 : 영문 339 Pages

세계의 전립선암(Prostate Cancer) 치료 시장에 대해 조사했으며, 시장 분석(과거 6년간 실적), 제품 개요, 최근의 시장 활동, 세계 시장 동향 전망(향후 8년간 예측), 지역별·주요 국가별 시장 동향, 주요 기업 프로파일 등의 정보를 전해드립니다.

제1장 서론, 조사 방법, 제품 정의

제2장 개요

  • 산업 개요
    • 서론
    • 신제품 출시에 의한 전립선암 치료 시장 급성장
    • 호르몬 요법이 시장의 대부분을 차지
    • 표적치료 : 암치료의 뉴프론티어
    • 방사선 치료 : 보급률 상승
    • 약물전달 기술의 혁신 : 제품 차별화 주요인
    • 새로운 치료법의 출현
    • 소규모 기업 : 민간자본 투자의 주대상
    • 최소침습 치료기기 : 신흥시장으로의 보급 움직임
    • 유럽 시장 : 사회적 인지도 상승이 시장 성장 촉진
    • 성장 촉진요인
    • 성장 억제요인
  • 임상시험 현황
    • 파이프라인 후보의약품
    • 전임상 단계 의약품
    • 출시 의약품
  • 제품 개요
    • 암 : 현대 사회의 가장 큰 건강 문제
    • 전립선의 구조
    • 전립선암 : 개요
    • 전립선암 검사 및 발견 방법
    • 전립선암 검사 및 발견 추진 전략
    • 전립선암의 병기(staging)
    • 유전/비유전 요인
    • 암 예방
    • 전립선암 예방에서 식사의 역할
  • 전립선암 치료 옵션
    • 호르몬 치료
    • 방사선 치료
    • 화학 치료
    • 전립선암 수술
    • 기타 치료 옵션
    • 최적의 치료 옵션 선택
    • 재발 전립선암
      • 수술후 재발
      • 방사선 치료후 재발
      • 호르몬 치료 저항성 전립선암(HRPC)
      • 재발 전립선암 치료 강화 전략
  • 신약 인증 및 임상시험 동향(총 38건)
  • 제품 개발 및 발매(총 8건)
  • 최근의 업계 활동(총 73건)
  • 주요 기업 분석(총 23개사)
  • 세계 시장 전망

제3장 시장

  • 미국
  • 유럽
    • 프랑스
    • 독일
    • 이탈리아
    • 영국
    • 스페인
    • 기타 유럽 국가
  • 기타 국가(RoW)

제4장 경쟁 환경

LSH 16.06.28

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

This report analyzes the worldwide markets for Prostate Cancer Therapeutics in US$ Million by the following Segments: Hormone Therapy, and Other Therapies. The report provides separate comprehensive analytics for the US, Canada, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 76 companies including many key and niche players such as -

AbbVie, Inc.
Allergan plc
Amgen, Inc.
Astellas Pharma, Inc.
AstraZeneca Plc
Bayer AG

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations

Disclaimers

Data Interpretation & Reporting Level

  • Quantitative Techniques & Analytics

Product Definitions and Scope of Study

  • Hormone Therapy
  • Other Therapies
    • Radiation Therapy
    • Immunotherapy
    • Chemotherapy

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW

  • An Insight in the Global Market for Prostate Cancer Diagnostics and Therapeutics
  • Rising Incidence of Prostate Cancer: Cornerstone for the Market
    • Table 1: Global Cancer Incidence (2015): Number of New Cancer Cases in Thousands by Type and Gender (includes corresponding Graph/Chart)
    • Table 2: Global Cancer Mortality (2015): Number of Cancer Related Deaths in Thousands by Type and Gender (includes corresponding Graph/Chart)
    • Table 3: Prostate Cancer Incidence Worldwide: Comparative Analysis for the Years 2004, 2007, 2012 and 2015 (includes corresponding Graph/Chart)
  • Current & Future Analysis
  • Developed Markets: Traditional Revenue Contributors
    • Table 4: Healthcare Spending as a Percentage of GDP by Region (2016) (includes corresponding Graph/Chart)
  • Developing Countries Turbo Charge Future Market Growth
  • An Insight into the Castration-Resistant Prostate Cancer Therapeutics Market
  • Market Outlook & Trends
  • Zytiga (Abiraterone acetate): The Market Leader
    • Table 5: Global Sales of Leading Prostate Cancer Drugs in US$ Million: 2017 (includes corresponding Graph/Chart)
    • Select Drugs that Received Approval for Castration-Resistant Prostate Cancer (CRPC)
  • Hormone Therapies to Dominate Global Prostate Cancer Therapeutics Market
    • Key Prostate Cancer Hormone Therapy Drugs & Companies: 2017
  • Targeted Therapy - The New Frontier of Cancer Treatment
  • Radiotherapy - Gaining Prominence
  • Metastatic Prostate Cancer - Apt for Precision Oncology
  • Launch of Generic Drugs to Place Established Players in Jeopardy
  • Demographics & Lifestyles Raise the Risk of Prostate Cancer
    • Table 6: Probability of Developing Invasive Prostate Cancer by Age Group in the US: 2012-2014 (includes corresponding Graph/Chart)
  • Select General Risk Factors and their Relative Risk Rate in Prostate Cancer
  • Small Cap Companies: A Target of Private Capital Financing
  • Cost Analysis of Currently Available Treatment
    • Table 7: Prices of Xtandi by Country (2016): Prices of Xtandi 40 mg Capsule/Tabs in the US and Other High-Income Countries (includes corresponding Graph/Chart)
  • Growth Drivers
  • Rise in Prostate Cancer Incidence & Access to Modern Therapeutics Foster Growth
  • Improved Screening, Diagnosis & Patient Survival Rates Trigger Growth
    • Table 8: Five-Year Prostate Cancer Survival Rate (%) Among US Males (2007-2013)
  • Awareness Drives European Prostate Cancer Therapeutics Market
  • Minimally Invasive Devices to Gain Share in Emerging Markets
  • Supportive Cancer Drugs Contribute to Growth
    • Select FDA Approved Drugs for Palliative Treatment of Advanced Prostate Cancer
  • Developments in Proteomics Favor Market
  • Molecular Imaging of Cancer: Critical in Improving Patient Outcomes
  • Growth Restraints
  • Costly & Complicated Treatment Protocols: A Major Stumbling Block in Patient Compliance
  • Limited Tumor Specificity and Toxicity
  • Multiple Drug Resistance
  • Stringent Regulations Delay Market Approval
  • Challenges Faced by Patients and Clinicians in Diagnosis and Treatment
  • Challenges Encountered in Clinical Trials
    • Select Recent Prostate Cancer Drug Trial Failures
  • High Development Costs Retracts Manufacturers in Developing Countries
  • Pipeline of Drugs in Clinical Trials
  • New Products to Bolster Sales of Prostate Cancer Therapeutics
    • Select Prostate Cancer Drugs in the Pipeline (2018)
  • Marine Sponge-Derived Compound Shows Promise against Prostate Cancer
  • New Combination Treatment for Advanced mCRPC
  • Risk of Alzheimer's dampens the Market
  • Innovations & Advancements
  • Research and Development Findings
  • Additional Tests to be used with PSA for Better Diagnosis of Prostate Cancer
  • New Approaches in Diagnosis and Staging of Prostate Cancer
  • New Developments in Treatment Methods and Diet Strategies
  • Innovative mCRPC Treatment Options to Enhance Quality of Life
  • New Drug Class (sphingolipid pathway inhibitor) Shows Potential for Slowing down Growth
  • Neural Stem Cell Therapy: Revolutionary Step to Combat Cancer
  • Ailanthone Identified as Potential Therapeutic for the Treatment of CRPC
  • Laser Activated Treatment for Prostate Cancer Developed
  • Photodynamic Therapy Offers Potential to Treat Prostate Cancer
  • Combination of Therapies under Research
  • Future Research Strategies to Benefit from Open Access Publishing
  • Innovations in Drug Delivery: A Key Factor in Product Differentiation

2. PRODUCT OVERVIEW

  • Cancer: A Major Health Crisis in the Modern World
  • Prostate - Structure
  • Pituitary Gland
  • Testes
  • Prostate Cancer - A Primer
  • Key Facts
    • Table 9: Lifetime Probability of Developing Prostate Cancer by Age in % and Odds - 2010-2015 (includes corresponding Graph/Chart)
    • Table 10: Prostate Cancer Incidence and Mortality Rate in the World by Region: 2015 (includes corresponding Graph/Chart)
  • Screening/Detection of Prostate Cancer
  • Digital Rectal Exam (DRE)
  • Transrectal Ultrasound (TRUS)
  • PSA Blood Test
  • Strategies to Enhance Screening/Detection of Prostate Cancer
  • Improved PSA Testing
  • Total PSA, Free PSA and PSA-Alpha-1-Protease Inhibitor Levels
  • Insulin-like Growth Factor (IGF-1) and Intact IGF-Binding Protien-3 (IGF-BP3)
  • GSTP1 Methylation Levels and Prostate Cancer Diagnosis
  • Microbubble Ultrasound
  • Staging of Prostate Cancer
  • Gleason Score
    • Gleason Score and Grading of Prostate Cancer
  • TNM Staging
    • T-Staging Analysis of Prostate Cancer
  • Genetic & Non-Genetic Factors
  • Hereditary or Genetic Factors
  • Non-Genetic or Environmental Factors
    • Table 11: Prostate Cancer Incidence/Mortality Rate in the US by Ethnicity (2010-2014) (includes corresponding Graph/Chart)
  • Prevention of Cancer
  • Role of Diet in Prostate Cancer
  • Treatment Options for Prostate Cancer
  • Hormonal Therapy
  • Medical Hormone Therapy
  • LHRH Analogs
    • Dose of LHRH Agonists for Advance Prostate Carcinoma Treatment
  • Anti-Androgens
    • Anti-Androgen Monotherapy
  • Orchiectomy
    • Side Effects of Orchiectomy
  • Time to Start Hormonal Therapy
  • Strategies to Enhance Hormonal Treatment
    • Combination Therapy
    • Intermittent Therapy
  • Radiation Therapy
  • Brachytherapy
    • Table 12: Brachytherapy Market by Application Area (2017): Percentage Share Breakdown for Breast, Gynecology, Prostate and Others (includes corresponding Graph/Chart)
    • Treatment Procedure
    • Benefits of Brachytherapy
    • Drawbacks of Brachytherapy
    • High Dose Rate (HDR) Brachytherapy
  • External Beam Radiation Therapy (EBRT)
  • Side Effects of Radiotherapy
  • Strategies to Enhance Radiation Treatment
  • Chemotherapy
  • Risks Associated with Chemotherapy
  • Surgical Procedures for Prostate Cancer
  • Transurethral Resection of the Prostate (TURP)
  • Prostatectomy and Lymph Node Dissection
  • Radical Prostatectomy
  • Cryosurgery
    • Advantages of Cryosurgery:
    • Disadvantages of Cryosurgery:
  • Other Treatment Options
  • Intensity Modulated Radiation Therapy (IMRT)
    • Benefits of IMRT
    • Drawbacks of IMRT
  • Androgen Deprivation Therapy (ADT)
  • High Dose Radiation (HDR) Monotherapy
    • Drawbacks of HRD
  • Choosing the Optimal Treatment Method...
  • Recurrent Prostate Cancer
  • Recurrent Prostate Cancer Subsequent to Surgery
  • Recurrent Prostate Cancer Subsequent to Radiation Therapy
  • Hormone-Refractory Prostate Cancer (HRPC)
    • Select Drugs for Hormone-Refractory Prostate Cancer
  • Chemotherapy
  • Taxotere(r) (Docetaxel)
  • Bone Complication Treatments
  • Bisphosphonate Drugs
  • Radiation Therapy
  • Strategies to Enhance Recurrent Prostate Cancer Treatment
  • Chemotherapy - New Regimens
  • Phase I Clinical Trials
  • Combination Therapy
  • Gene Therapy
  • Targeted Therapy
  • Selective Endothelia A Receptor Antagonist - (SERA(tm))
  • Other Select Targeted Therapies
    • Tyrosine Kinase Inhibitors
    • Anti-Angiogenic Drugs
    • Monoclonal Antibodies
    • Vaccines
    • Radioactive Monoclonal Antibodies
  • Distribution Channels

3. DRUG APPROVALS AND CLINICAL STUDIES

  • Janssen Biotech Receives Approval for Erleada
  • Janssen Pharmaceutical Bags Approval for ZYTIGA(r) for Metastatic High-Risk CSPC
  • Janssen Biotech Submits Supplemental NDA for ZYTIGA(r) to Treat Early Stage Metastatic Prostate Cancer
  • Bavarian Nordic to Discontinue Phase 3 PROSPECT Study on mCRPC
  • Bavarian Nordic Announces Phase 2 Clinical Trial of PROSTVAC
  • OncBioMune Pharmaceuticals Offers Latest Clinical Data of ProscaVax
  • Pfizer and Astellas Pharma Announces Phase 3 PROSPER Trial Results of XTANDI(r)
  • EMA Issues Positive Opinion to Include Data in European Label for XTANDI
  • Cofepris Approves Weizmann Institute Drug TOOKAD(r) Soluble
  • OncBioMune Pharmaceuticals Reports Positive Phase 1 Results of ProscaVax
  • FDA Accepts Xtandi sNDA by Astellas Pharma for Review
  • Progenics Pharmaceuticals Begins Phase 3 Clinical Trial Enrollment for 1404
  • FDA Grants Astrazeneca's Lynparza(tm) Breakthrough Therapy Designation
  • Nanobiotix's Investigational New Drug NBTXR3 Set for First Clinical Trial
  • Minomic International to Launch Human Trial of Its MAb Technology
  • Takeda Receives NDA Approval for Leuplin
  • Progenics Enters into Licensing Agreement with Johns Hopkins for Clinical-Stage PSMA Agent
  • ZYTIGA Receives FDA Approval for Label Update
  • Valeant Reports Long-Term results of Phase II STAND Trial of PROVENGE
  • OncoGeneX Pharmaceuticals to Regain Rights on Experimental Drug Custirsen from Teva

4. PRODUCT LAUNCHES

  • QIAGEN Commercializes AdnaTest Prostate Cancer Panel AR-V7 for Research Use
  • GenomeDx Biosciences Launches Decipher Biopsy Test for Prostate Cancer
  • Profound Medical and Siemens Sign Agreement to Launch TULSA-PROTM System
  • Aeterna Zentaris Begins Promotional Activities for APIFINY(r) Test
  • Biocept Launches Androgen Receptor Expression Assay for Prostate Cancer Detection
  • Augmenix Reports Robust Commercial Uptake of SpaceOAR(r) System during Radiotherapy
  • MDxHealth SA Launches SelectMDx Test in Europe
  • Bayer Launches Xofigo in Ontario

5. RECENT INDUSTRY ACTIVITY

  • Valeant Pharmaceuticals International to Divest Dendreon Pharmaceuticals to Sanpower Group
  • AbbVie Enters into Immuno-Oncology Research Collaboration with Harpoon Therapeutics
  • AstraZeneca Inks Pact with TerSera Therapeutics
  • Bristol-Myers Squibb and Clovis Oncology Ink a Broad Clinical Collaboration Agreement
  • J&J Expands Market for Zytiga
  • Telix Pharmaceuticals Completes Product Collaboration and Purchase Option Agreement with Atlab Pharma
  • UCLA Sells Xtandi Rights to Royalty Pharma
  • Aytu BioScience Enters into Study Agreement with Hybridyne Imaging Technologies
  • Crown Bioscience Signs Licensing Agreement with University of York for PDX Models
  • Hologic Acquires DiagnoCure's Prostate Cancer Biomarker Assets
  • Aeterna Zentaris Enters into Co-Marketing Agreement with Armune
  • Exiqon Acquires Licensing Rights on Prostate Cancer Biomarkers from University Hospital
  • Mylan Sued for ANDA for Generic Version of Zytiga
  • Aytu BioScience Acquires Jazz Pharmaceuticals' rights to ProstaScint
  • OPKO Health to Acquire Bio-Reference Laboratories
  • Boston Scientific to Acquire American Medical Systems' Urology Portfolio
  • Valeant to Acquire Dendreon's Assets

6. FOCUS ON SELECT GLOBAL PLAYERS

  • AbbVie, Inc. (USA)
  • Allergan plc (Ireland)
  • Amgen, Inc. (USA)
  • Astellas Pharma, Inc. (Japan)
  • AstraZeneca Plc. (UK)
  • Bayer AG (Germany)
  • Bristol-Myers Squibb Company (USA)
  • Debiopharm Group (Switzerland)
  • Dendreon Pharmaceuticals LLC (USA)
  • Endo Pharmaceuticals Inc. (USA)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Genentech Inc. (USA)
  • GlaxoSmithKline Plc. (UK)
  • Janssen Biotech, Inc. (USA)
  • Myovant Sciences Ltd. (UK)
  • Novartis AG (Switzerland)
  • Pfizer, Inc. (USA)
  • Progenics Pharmaceuticals, Inc. (USA)
  • Sanofi S.A. (France)
  • Spectrum Pharmaceuticals, Inc. (USA)
  • Takeda Pharmaceutical Company Limited (Japan)
  • TOLMAR Pharmaceuticals, Inc. (USA)

7. GLOBAL MARKET PERSPECTIVE

    • Table 13: World Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Geographic Region/Country - US, Canada, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 14: World Historic Review for Prostate Cancer Therapeutics by Geographic Region/Country - US, Canada, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 15: World 14-Year Perspective for Prostate Cancer Therapeutics by Geographic Region/Country - Percentage Breakdown of Dollar Sales for US, Canada, Europe, and Rest of World Markets for Years 2009, 2018 and 2022 (includes corresponding Graph/Chart)
  • Segmental Analytics
    • Table 16: World Recent Past, Current & Future Analysis for Hormone Therapy by Geographic Region/Country - US, Canada, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 17: World Historic Review for Hormone Therapy by Geographic Region/Country - US, Canada, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 18: World 14-Year Perspective for Hormone Therapy by Geographic Region/Country - Percentage Breakdown of Dollar Sales for US, Canada, Europe, and Rest of World Markets for Years 2009, 2018 and 2022 (includes corresponding Graph/Chart)
    • Table 19: World Recent Past, Current & Future Analysis for Other Therapies by Geographic Region/Country - US, Canada, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 20: World Historic Review for Other Therapies by Geographic Region/Country - US, Canada, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 21: World 14-Year Perspective for Other Therapies by Geographic Region/Country - Percentage Breakdown of Dollar Sales for US, Canada, Europe, and Rest of World Markets for Years 2009, 2018 and 2022 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

  • A. Market Analysis
    • A Surging US Prostate Cancer Therapeutics Market
    • Table 22: Cancer Incidence and Mortality (in Men) in the US by Type: 2018E (includes corresponding Graph/Chart)
    • Prostate Cancer Stats: Opportunity Indicator
    • Table 23: Prostate Cancer Incidence and Mortality in the US by Select Leading States (2018E): No. of New Cancer Cases and No. of Deaths from Prostate Cancer (includes corresponding Graph/Chart)
    • Table 24: Prostate Cancer Incidence in the US by Age Group: 2017 (includes corresponding Graph/Chart)
    • Table 25: Probability of Development of Prostate Cancer (in Men) by Age Group in the US, 2012-2014 (includes corresponding Graph/Chart)
    • Hormone Therapy Dominates Prostate Cancer Drugs Market
    • Table 26: Sales of Leading Prostate Cancer Drugs in US$ Million in the US: 2017 (includes corresponding Graph/Chart)
    • High Intensity Focused Ultrasound (HIFU) Approved for Ablation of Prostate Tissue
    • Drug Approvals and Clinical Studies
    • Product Launches
    • Strategic Corporate Developments
    • Select Key Players
  • B. Market Analytics
    • Table 27: The US Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Type - Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 28: The US Historic Review for Prostate Cancer Therapeutics by Type - Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 29: The US 14-Year Perspective for Prostate Cancer Therapeutics by Type - Percentage Breakdown of Dollar Sales for Hormone Therapy and Other Therapies Markets for Years 2009, 2018 and 2022 (includes corresponding Graph/Chart)

2. CANADA

  • A. Market Analysis
    • Prostate Cancer Stats: Opportunity Indicators
    • Table 30: New Cancer Cases for Male in Canada by Type (2017): Breakdown of New Cancer Cases Diagnosed for Prostate, Colorectal, Lung & Bronchus, Bladder, Non-Hodgkin Lymphoma, and Others (includes corresponding Graph/Chart)
    • Table 31: Prostate Cancer Incidence and Mortality in Canada by Leading Province: 2017 (includes corresponding Graph/Chart)
    • Table 32: Prostate Cancer Incidence and Mortality in Canada by Age Group: 2017 (includes corresponding Graph/Chart)
    • Clinical Trial
    • Product Launches
    • Strategic Corporate Developments
  • B. Market Analytics
    • Table 33: Canadian Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Type - Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 34: Canadian Historic Review for Prostate Cancer Therapeutics by Type - Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 35: Canadian 14-Year Perspective for Prostate Cancer Therapeutics by Type - Percentage Breakdown of Dollar Sales for Hormone Therapy and Other Therapies Markets for Years 2009, 2018 and 2022 (includes corresponding Graph/Chart)

3. EUROPE

  • A. Market Analysis
    • Awareness Drives European Prostate Cancer Therapeutics Market
    • Table 36: Cancer Mortality in the European Union: Percentage Breakdown of Number of Deaths by Cancer Type in 2017 (includes corresponding Graph/Chart)
    • HIFU Technology Gaining Momentum in Europe
  • B. Market Analytics
    • Table 37: European Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Geographic Region/Country - France, Germany, Italy, United Kingdom, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 38: European Historic Review for Prostate Cancer Therapeutics by Geographic Region/Country - France, Germany, Italy, United Kingdom, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 39: European 14-Year Perspective for Prostate Cancer Therapeutics by Geographic Region/Country - Percentage Breakdown of Dollar Sales for France, Germany, Italy, United Kingdom, Spain, and Rest of Europe Markets for Years 2009, 2018 and 2022 (includes corresponding Graph/Chart)
    • Table 40: European Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Type - Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 41: European Historic Review for Prostate Cancer Therapeutics by Type - Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 42: European 14-Year Perspective for Prostate Cancer Therapeutics by Type - Percentage Breakdown of Dollar Sales for Hormone Therapy and Other Therapies Markets for Years 2009, 2018 and 2022 (includes corresponding Graph/Chart)

3a. FRANCE

  • A. Market Analysis
    • Sanofi S.A. - A Key France-based Player
  • B. Market Analytics
    • Table 43: French Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Type - Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 44: French Historic Review for Prostate Cancer Therapeutics by Type - Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 45: French 14-Year Perspective for Prostate Cancer Therapeutics by Type - Percentage Breakdown of Dollar Sales for Hormone Therapy and Other Therapies Markets for Years 2009, 2018 and 2022 (includes corresponding Graph/Chart)

3b. GERMANY

  • A. Market Analysis
    • Product Launch
    • Select Key Player
  • B. Market Analytics
    • Table 46: German Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Type - Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 47: German Historic Review for Prostate Cancer Therapeutics by Type - Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 48: German 14-Year Perspective for Prostate Cancer Therapeutics by Type - Percentage Breakdown of Dollar Sales for Hormone Therapy and Other Therapies Markets for Years 2009, 2018 and 2022 (includes corresponding Graph/Chart)

3c. ITALY

  • Market Analysis
    • Table 49: Italian Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Type - Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 50: Italian Historic Review for Prostate Cancer Therapeutics by Type - Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 51: Italian 14-Year Perspective for Prostate Cancer Therapeutics by Type - Percentage Breakdown of Dollar Sales for Hormone Therapy and Other Therapies Markets for Years 2009, 2018 and 2022 (includes corresponding Graph/Chart)

3d. THE UNITED KINGDOM

  • A. Market Analysis
    • Table 52: Cancer Incidence and Mortality in the UK by Type: 2015 (includes corresponding Graph/Chart)
    • Prostate Cancer Research in UK - An Insight
    • Need for Filling up Gaps in Provision of Care
    • Dearth of Clinical Researchers
    • Select Key Players
  • B. Market Analytics
    • Table 53: The UK Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Type - Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 54: The UK Historic Review for Prostate Cancer Therapeutics by Type - Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 55: The UK 14-Year Perspective for Prostate Cancer Therapeutics by Type - Percentage Breakdown of Dollar Sales for Hormone Therapy and Other Therapies Markets for Years 2009, 2018 and 2022 (includes corresponding Graph/Chart)

3e. SPAIN

  • Market Analysis
    • Table 56: Spanish Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Type - Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 57: Spanish Historic Review for Prostate Cancer Therapeutics by Type - Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 58: Spanish 14-Year Perspective for Prostate Cancer Therapeutics by Type - Percentage Breakdown of Dollar Sales for Hormone Therapy and Other Therapies Markets for Years 2009, 2018 and 2022 (includes corresponding Graph/Chart)

3f. REST OF EUROPE

  • A. Market Analysis
    • Clinical Studies
    • Product Launch
    • Strategic Corporate Development
    • Select Key Players
  • B. Market Analytics
    • Table 59: Rest of European Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Type - Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 60: Rest of European Historic Review for Prostate Cancer Therapeutics by Type - Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 61: Rest of European 14-Year Perspective for Prostate Cancer Therapeutics by Type - Percentage Breakdown of Dollar Sales for Hormone Therapy and Other Therapies Markets for Years 2009, 2018 and 2022 (includes corresponding Graph/Chart)

4. REST OF WORLD

  • A. Market Analysis
    • Minimally Invasive Devices to Gain Share in Emerging Markets
    • Cancer Market in Asia
      • Australia
      • India
    • Table 62: New Incidence Rate of Prostate Cancer (Rate per Million Population) in Asia-Pacific and Latin America for 2012
    • Table 63: 5-Year Net Survival Rates (%) for Prostate Cancer among Adults 15 Years of Age and Older (2005-2009) in Select Asian and Latin American Countries (includes corresponding Graph/Chart)
    • Clinical Trials
    • Select Key Players
  • B. Market Analytics
    • Table 64: Rest of World Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Type - Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 65: Rest of World Historic Review for Prostate Cancer Therapeutics by Type - Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 66: Rest of World 14-Year Perspective for Prostate Cancer Therapeutics by Type - Percentage Breakdown of Dollar Sales for Hormone Therapy and Other Therapies Markets for Years 2009, 2018 and 2022 (includes corresponding Graph/Chart)
Back to Top
전화 문의
F A Q
 
BCC Research